OKYO Pharma Limited announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, highlighting a strengthened cash position of approximately $20.6 million as of March 2026. The company successfully completed a public offering in February 2026 that raised approximately $22 million in gross proceeds. These funds are intended to secure funding through the completion of the FDA-agreed global Phase 3 pivotal trial, the NEPTUNE trial, for its lead candidate urcosimod, which is planned to initiate in the second half of 2026. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
